Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease
作者： Ioannis E. Koutroubakis , Aekaterini Sfiridaki , Georgia Tsiolakidou , Constantina Coucoutsi , Angeliki Theodoropoulou
DOI: 10.1097/MEG.0B013E3282FAA759
关键词:
摘要: BackgroundPatients with inflammatory bowel disease (IBD) have an increased risk of thromboembolic events. Imbalance fibrinolysis has been suggested as one the possible pathogenetic mechanisms. As plasminogen activator inhibitor-1 (PAI-1) and thrombin-activatable inhibitor (TAFI) a
lww.com
sci-hub.se 参考文章(19)
P. Chetaille, M. C. Alessi, D. Kouassi, P. E. Morange, I. Juhan-Vague, Plasma TAFI antigen variations in healthy subjects. Thrombosis and Haemostasis. ,vol. 83, pp. 902- 905 ,(2000) , 10.1055/S-0037-1613941
A. A. Van Bodegraven, H. A. R. E. Tuynman, M. Schoorl, A. M. Kruishoop, P. C. M. Bartels, Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease. Scandinavian Journal of Gastroenterology. ,vol. 30, pp. 580- 585 ,(1995) , 10.3109/00365529509089793
Yuichi Morohoshi, Katsuyoshi Matsuoka, Hiroshi Chinen, Nobuhiko Kamada, Toshiro Sato, Tadakazu Hisamatsu, Susumu Okamoto, Nagamu Inoue, Hiromasa Takaishi, Haruhiko Ogata, Yasushi Iwao, Toshifumi Hibi, Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis. Journal of Gastroenterology. ,vol. 41, pp. 318- 324 ,(2006) , 10.1007/S00535-005-1768-8
Ioannis E Koutroubakis, Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nature Clinical Practice Gastroenterology & Hepatology. ,vol. 2, pp. 266- 272 ,(2005) , 10.1038/NCPGASTHEP0190
S. Saibeni, B. Bottasso, L. Spina, M. Bajetta, S. Danese, A. Gasbarrini, R. de Franchis, M. Vecchi, Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. The American Journal of Gastroenterology. ,vol. 99, pp. 1966- 1970 ,(2004) , 10.1111/J.1572-0241.2004.30203.X
Peter Weber, Stephanie Husemann, Heinrich Vielhaber, Klaus-Peter Zimmer, Ulrike Nowak-Göttl, Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. ,vol. 28, pp. 418- 422 ,(1999) , 10.1097/00005176-199904000-00013
M. Hudson, R. A. Hutton, A. J. Wakefield, A. M. Sawyerr, R. E. Pounder, Evidence for activation of coagulation in Crohn's disease. Blood Coagulation & Fibrinolysis. ,vol. 3, pp. 773- 778 ,(1992) , 10.1097/00001721-199212000-00011
E de Jong, R J Porte, E A Knot, J H Verheijen, J Dees, Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. Gut. ,vol. 30, pp. 188- 194 ,(1989) , 10.1136/GUT.30.2.188
S. SAIBENI, C. CISCATO, M. VECCHI, M. BOSCOLO ANZOLETTI, E. KACZMAREK, S. CACCIA, R. DE FRANCHIS, M. CUGNO, Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. Journal of Thrombosis and Haemostasis. ,vol. 4, pp. 1510- 1516 ,(2006) , 10.1111/J.1538-7836.2006.01970.X
J. E. Lennard-Jones, Classification of inflammatory bowel disease. Scandinavian Journal of Gastroenterology. ,vol. 170, pp. 2- 6 ,(1989) , 10.3109/00365528909091339